Status:
WITHDRAWN
Lithium Versus Paroxetine in Major Depression
Lead Sponsor:
Nova Scotia Health Authority
Conditions:
Major Depressive Disorder
Eligibility:
All Genders
18+ years
Phase:
PHASE4
Brief Summary
This study is being done to look at how well people respond to two different drug treatments for depression. Clinically, people can respond differently to different treatments for reasons which are no...
Detailed Description
Lithium is a mood stabilizing drug that has been used to treat people with both bipolar disorder and depression for the last 50 years. It is available to the public by prescription in Canada and has b...
Eligibility Criteria
Inclusion
- men or women
- age of 18 years or older
- meet criteria for major depressive episode, and have a family history of bipolar disorder or completed suicide
Exclusion
- subjects not able to give informed consent
- pregnant or breast-feeding women
- current panic disorder, post traumatic stress disorder or psychosis
- subjects with a history of mania or hypomania
- subjects with active substance abuse or dependence in the last 6 months
- current depressive episode less than 4 weeks or greater than 12 months in duration
- adequate trial of lithium or paroxetine (lithium level ≥ 0.6mmols/l; paroxetine 20mgs ≥ 5 weeks) for this episode of depression
- concurrent use of other antidepressants or augmenting agents for the treatment of depression
- clinically significant medical illness, in particular renal impairment
Key Trial Info
Start Date :
September 1 2011
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
February 1 2013
Estimated Enrollment :
Patients enrolled
Trial Details
Trial ID
NCT01416220
Start Date
September 1 2011
End Date
February 1 2013
Last Update
September 19 2024
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Queen Elizabeth II Health Sciences Centre
Halifax, Nova Scotia, Canada, B3H 2E2